Christian Brandl

Amgen (Germany) — Germany

Medicine · Health Sciences

14h-index3.1kcitations30works7.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(18), Monoclonal and Polyclonal Antibodies Research(17), Acute Lymphoblastic Leukemia research(6), Immunotherapy and Immune Responses(5), Glycosylation and Glycoproteins Research(5)

Publications30 total

Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE®) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study
Clinical Pharmacokinetics·2024· 7 cited
Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy
Frontiers in Immunology·2023· 21 citedOpen Access
Data from Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule
2023Open Access
Data from Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule
2023Open Access
Supplementary Data from Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule
2023Open Access
Supplementary Data from Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule
2023Open Access
Data from Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events
2023Open Access
Supplementary Data from Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events
2023Open Access
Data from Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events
2023Open Access
Supplementary Data from Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events
2023Open Access
Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule
Molecular Cancer Therapeutics·2021· 10 citedOpen Access
Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events
Cancer Research·2019· 77 citedOpen Access
Issue Information
The Journal of Clinical Pharmacology·2018Open Access
Blinatumomab Pharmacodynamics and Exposure–Response Relationships in Relapsed/Refractory Acute Lymphoblastic Leukemia
The Journal of Clinical Pharmacology·2017· 34 cited
Pathogenesis-Based Development of Potential Mitigation Strategies for Blinatumomab-Associated Neurologic Events (NEs)
Blood·2016· 8 cited
Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications
Clinical Pharmacokinetics·2016· 203 cited
Pharmacokinetics/pharmacodynamics (PKPD) of blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).
Journal of Clinical Oncology·2015· 7 cited
AB0023 In Vivo Effects of Epratuzumab, A Monoclonal Antibody Targeting Human CD22, on B Cell Function in Human CD22 Knock-In (HUKI) Mice
Annals of the Rheumatic Diseases·2014· 2 cited
Pharmacokinetics (PK) of blinatumomab and its clinical implications.
Journal of Clinical Oncology·2013· 15 cited
Immunopharmacodynamic response to blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).
Journal of Clinical Oncology·2013· 8 cited
page 1 of 2Next →

Frequent Co-authors

Ralf C. Bargou(15), Peter Kufer(15), Gerhard Zugmaier(10), Andreas Wolf(9), Patrick A. Baeuerle(9), Matthias Klinger(6), Matthias Stelljes(6), Petra Deegen(6), Benno Rattel(6), Virginie Nägele(6), Maria-Elisabeth Goebeler(5), Hans Lassmann(5), Arend von Stackelberg(5), Elizabeth Pham(5), Matthias G. Friedrich(5), Famke Aeffner(5), Michael Lutteropp(5), Natalie F. Mariano(5), Franziska Vogel(5), Claudia Bluemel(5)